These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
468 related items for PubMed ID: 21952518
1. Plasma C-terminal pro-endothelin-1 and the natriuretic pro-peptides NT-proBNP and MR-proANP in very preterm infants with patent ductus arteriosus. Letzner J, Berger F, Schwabe S, Benzing J, Morgenthaler NG, Bucher HU, Bührer C, Arlettaz R, Wellmann S. Neonatology; 2012; 101(2):116-24. PubMed ID: 21952518 [Abstract] [Full Text] [Related]
6. Correlation analysis between echocardiographic flow pattern and N-terminal-pro-brain natriuretic peptide for early targeted treatment of patent ductus arteriosus. Occhipinti F, De Carolis MP, De Rosa G, Bersani I, Lacerenza S, Cota F, Rubortone SA, Romagnoli C. J Matern Fetal Neonatal Med; 2014 Nov; 27(17):1800-4. PubMed ID: 24397409 [Abstract] [Full Text] [Related]
7. N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants. Nuntnarumit P, Khositseth A, Thanomsingh P. J Perinatol; 2009 Feb; 29(2):137-42. PubMed ID: 19020527 [Abstract] [Full Text] [Related]
8. Stable precursor fragments of vasoactive peptides in umbilical cord blood of term and preterm infants. Koch L, Dabek MT, Frommhold D, Poeschl J. Horm Res Paediatr; 2011 Feb; 76(4):234-9. PubMed ID: 21893934 [Abstract] [Full Text] [Related]
9. [Value of amino-terminal pro-brain natriuretic peptide as a predictive marker of symptomatic patent ductus arteriosus in preterm infants]. Lu KS, Guo XL, Lv JF, Huang SL, Yang CH, Zou ZH, Chen ZJ, Lai CH, Yang BY. Zhongguo Dang Dai Er Ke Za Zhi; 2015 Nov; 17(11):1160-4. PubMed ID: 26575871 [Abstract] [Full Text] [Related]
15. Early NT-proBNP is able to predict spontaneous closure of patent ductus arteriosus in preterm neonates, but not the need of its treatment. Martinovici D, Vanden Eijnden S, Unger P, Najem B, Gulbis B, Maréchal Y. Pediatr Cardiol; 2011 Oct; 32(7):953-7. PubMed ID: 21656237 [Abstract] [Full Text] [Related]
16. Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events. van Hateren KJ, Alkhalaf A, Kleefstra N, Groenier KH, de Jong PE, de Zeeuw D, Gans RO, Struck J, Bilo HJ, Gansevoort RT, Bakker SJ. Clin Chem; 2012 Jan; 58(1):293-7. PubMed ID: 21948291 [Abstract] [Full Text] [Related]
17. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease. Elmas E, Brueckmann M, Lang S, Kälsch T, Haghi D, Sueselbeck T, Dempfle CE, Borggrefe M. Int J Cardiol; 2008 Aug 18; 128(2):244-9. PubMed ID: 17673312 [Abstract] [Full Text] [Related]
18. Utility of N-terminal pro-brain natriuretic peptide for assessing hemodynamic significance of patent ductus arteriosus in dogs undergoing ductal repair. Hariu CD, Saunders AB, Gordon SG, Norby B, Miller MW. J Vet Cardiol; 2013 Sep 18; 15(3):197-204. PubMed ID: 23933478 [Abstract] [Full Text] [Related]
19. Midregional pro-atrial natriuretic peptide for the diagnosis of cardiac-related dyspnea according to renal function in the emergency department: a comparison with B-type natriuretic peptide (BNP) and N-terminal proBNP. Chenevier-Gobeaux C, Guerin S, André S, Ray P, Cynober L, Gestin S, Pourriat JL, Claessens YE. Clin Chem; 2010 Nov 18; 56(11):1708-17. PubMed ID: 20813917 [Abstract] [Full Text] [Related]